Somewhat Favorable News Coverage Somewhat Unlikely to Affect Amedisys (AMED) Stock Price

News coverage about Amedisys (NASDAQ:AMED) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amedisys earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news stories about the health services provider an impact score of 46.4531117758324 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment’s analysis:

Shares of Amedisys (AMED) opened at $54.53 on Friday. Amedisys has a 52 week low of $39.95 and a 52 week high of $65.91. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.33 and a quick ratio of 1.33. The company has a market capitalization of $1,786.77, a PE ratio of 25.19, a PEG ratio of 1.27 and a beta of 0.70.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.02. The firm had revenue of $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.36 EPS. sell-side analysts predict that Amedisys will post 2.23 earnings per share for the current year.

A number of analysts have issued reports on the stock. BidaskClub raised shares of Amedisys from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Robert W. Baird reissued a “hold” rating and issued a $50.00 price target on shares of Amedisys in a report on Wednesday, October 4th. Mizuho reissued a “buy” rating and issued a $65.00 price target (up previously from $55.00) on shares of Amedisys in a report on Wednesday, November 8th. Benchmark restated a “hold” rating on shares of Amedisys in a research note on Thursday, November 9th. Finally, Bank of America started coverage on shares of Amedisys in a research note on Monday, August 21st. They issued a “neutral” rating and a $55.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $61.00.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Amedisys (AMED) Stock Price” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2017/12/08/amedisys-amed-earns-news-impact-rating-of-0-23-updated-updated.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply